These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 15604280

  • 1. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
    Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A.
    Cancer Res; 2004 Dec 15; 64(24):9105-14. PubMed ID: 15604280
    [Abstract] [Full Text] [Related]

  • 2. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
    Ravi R, Bedi A.
    Cancer Res; 2002 Mar 15; 62(6):1583-7. PubMed ID: 11912124
    [Abstract] [Full Text] [Related]

  • 3. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 4. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S, Almasan A.
    Cancer Res; 2003 Aug 01; 63(15):4713-23. PubMed ID: 12907654
    [Abstract] [Full Text] [Related]

  • 5. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA.
    Cancer Res; 2002 Oct 15; 62(20):5800-6. PubMed ID: 12384541
    [Abstract] [Full Text] [Related]

  • 6. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
    Malathi K, Paranjape JM, Ganapathi R, Silverman RH.
    Cancer Res; 2004 Dec 15; 64(24):9144-51. PubMed ID: 15604285
    [Abstract] [Full Text] [Related]

  • 7. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.
    Cancer Res; 2004 Jul 15; 64(14):4900-5. PubMed ID: 15256461
    [Abstract] [Full Text] [Related]

  • 8. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
    Wang S, El-Deiry WS.
    Proc Natl Acad Sci U S A; 2003 Dec 09; 100(25):15095-100. PubMed ID: 14645705
    [Abstract] [Full Text] [Related]

  • 9. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 10. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A.
    Cancer Res; 2006 May 15; 66(10):5363-70. PubMed ID: 16707463
    [Abstract] [Full Text] [Related]

  • 11. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
    He Q, Huang Y, Sheikh MS.
    Oncogene; 2004 Apr 01; 23(14):2554-8. PubMed ID: 14691451
    [Abstract] [Full Text] [Related]

  • 12. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
    He Q, Luo X, Huang Y, Sheikh MS.
    Oncogene; 2002 Sep 05; 21(39):6032-40. PubMed ID: 12203115
    [Abstract] [Full Text] [Related]

  • 13. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
    Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J, Escandón E.
    Oncogene; 2002 May 16; 21(22):3611-9. PubMed ID: 12032863
    [Abstract] [Full Text] [Related]

  • 14. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
    Du J, Wang Y, Chen D, Ji G, Ma Q, Liao S, Zheng Y, Zhang J, Hou Y.
    Cancer Lett; 2016 Dec 28; 383(2):145-153. PubMed ID: 27721019
    [Abstract] [Full Text] [Related]

  • 15. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice.
    Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandón E.
    Drug Metab Dispos; 2004 Nov 28; 32(11):1230-8. PubMed ID: 15282212
    [Abstract] [Full Text] [Related]

  • 16. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.
    LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A.
    Nat Med; 2002 Mar 28; 8(3):274-81. PubMed ID: 11875499
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C.
    Tillman DM, Izeradjene K, Szucs KS, Douglas L, Houghton JA.
    Cancer Res; 2003 Aug 15; 63(16):5118-25. PubMed ID: 12941843
    [Abstract] [Full Text] [Related]

  • 19. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
    Röhn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M.
    Oncogene; 2001 Jul 12; 20(31):4128-37. PubMed ID: 11464279
    [Abstract] [Full Text] [Related]

  • 20. Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.
    Sugamura K, Gibbs JF, Belicha-Villanueva A, Andrews C, Repasky EA, Hylander BL.
    Oncology; 2008 Jul 12; 74(3-4):188-97. PubMed ID: 18714167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.